Company: SCYX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001140361-25-016641
Chunk: 28

Company: SCYNEXIS INC
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 28
---
 is hereby APPROVED.” This is an advisory vote and the results will not be binding; however, we, our Board of Directors, and the Compensation Committee value the views of our stockholders and intend to consider the outcome of this vote when making future compensation decisions of our NEOs and on our executive compensation principles, policies, and procedures and will evaluate whether any actions are necessary to address the stockholders’ concerns. THE BOARD RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 3. 18

TABLE OF CONTENTS

EXECUTIVE OFFICERS OF THE COMPANY The following table sets forth information regarding our executive officers as of April 15, 2025:

| Name                   |     | Age |     | Position                             |
| David Angulo, M.D.     |     |  60 |     | Chief Executive Officer and Director |
| Ivor Macleod, MBA, CPA |     |  64 |     | Chief Financial Officer              |
| Scott Sukenick         |     |  47 |     | Chief Legal Officer                  |

Dr. Angulo ’s biography is included above under “Proposal 1 - Election of Directors.” Ivor Macleod, MBA, CPA, has served as our Chief Financial Officer since October 2022. Prior to joining SCYNEXIS, Mr. Macleod served as Chief Financial Officer at Athersys, Inc., a clinical stage biotechnology company focused on regenerative medicine, from January 2020 to October 2022, in which role he was responsible for the Finance, Accounting, Investor Relations, and Corporate Communications departments. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a Japanese research-based human health care company that discovers, develops and markets products globally, from 2015 to 2018, in which role he was responsible for the Finance, Accounting, and Commercial Analytics groups as well as overseeing both Corporate and Commercial Compliance. Prior to joining Eisai, Mr. Macleod served as Vice President Finance – Merck Research Labs at Merck & Co., Inc., a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, from 2012 to 2015. Before joining Merck, Mr. Macleod served from 1998 to 2012 at F. Hoffmann-La Roche, Inc., a multinational health care company, in